Evaluation of Acute Myeloid Leukemia Genomes using Genomic Proximity Mapping.
medRxiv
; 2024 Jun 01.
Article
de En
| MEDLINE
| ID: mdl-38853970
ABSTRACT
Background:
Cytogenetic analysis encompasses a suite of standard-of-care diagnostic testing methods that is routinely applied in cases of acute myeloid leukemia (AML) to assess chromosomal changes that are clinically relevant for risk classification and treatment decisions.Objective:
In this study, we assess the use of Genomic Proximity Mapping (GPM) for cytogenomic analysis of AML diagnostic specimens for detection of cytogenetic risk variants included in the European Leukemia Network (ELN) risk stratification guidelines.Methods:
Archival patient samples (N=48) from the Fred Hutchinson Cancer Center leukemia bank with historical clinical cytogenetic data were processed for GPM and analyzed with the CytoTerra® cloud-based analysis platform.Results:
GPM showed 100% concordance for all specific variants that have associated impacts on risk stratification as defined by ELN 2022 criteria, and a 72% concordance rate when considering all variants reported by the FH cytogenetic lab. GPM identified 39 additional variants, including variants of known clinical impact, not observed by cytogenetics.Conclusions:
GPM is an effective solution for the evaluation of known AML-associated risk variants and a source for biomarker discovery.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Langue:
En
Journal:
MedRxiv
Année:
2024
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique